Exosome from IFN-γ-Primed Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Improved Skin Inflammation and Barrier Function
Open Access
- 19 July 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11635
Abstract
The pathogenesis of atopic dermatitis (AD) is multifactorial, including immune dysregulation and epidermal barrier defects, and a novel therapeutic modality that can simultaneously target multiple pathways is needed. We investigated the therapeutic effects of exosomes (IFN-γ-iExo) secreted from IFN-γ-primed induced pluripotent stem cell-derived mesenchymal stem cells (iMSC) in mice with Aspergillus fumigatus-induced AD. IFN-γ-iExo was epicutaneously administered to mice with AD-like skin lesions. The effects of IFN-γ-iExo treatment were investigated through clinical scores, transepidermal water loss (TEWL) measurements, and histopathology. To elucidate the therapeutic mechanism, we used an in vitro model of human keratinocyte HaCaT cells stimulated with IL-4 and IL-13 and performed extensive bioinformatics analysis of skin mRNA from mice. The expression of indoleamine 2,3-dioxygenase was higher in IFN-γ primed iMSCs than in iMSCs. In human keratinocyte HaCaT cells, treatment with IFN-γ-iExo led to decreases in the mRNA expression of thymic stromal lymphopoietin, IL-25, and IL-33 and increases in keratin 1, keratin 10, desmoglein 1, and ceramide synthase 3. IFN-γ-iExo treatment significantly improved clinical and histological outcomes in AD mice, including clinical scores, TEWL, inflammatory cell infiltration, and epidermal thickness. Bioinformatics analysis of skin mRNA from AD mice showed that IFN-γ-iExo treatment is predominantly involved in skin barrier function and T cell immune response. Treatment with IFN-γ-iExo improved the clinical and histological outcomes of AD mice, which were likely mediated by restoring proper skin barrier function and suppressing T cell-mediated immune response.Keywords
Funding Information
- Korea Health Industry Development Institute (HI18C2439)
This publication has 44 references indexed in Scilit:
- How melanoma cells inactivate NK cellsOncoImmunology, 2012
- Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapyInternational Journal of Oncology, 2011
- Atopic dermatitis: a disease of altered skin barrier and immune dysregulationImmunological Reviews, 2011
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanismProceedings of the National Academy of Sciences, 2010
- Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated ImmunosuppressionStem Cells, 2009
- IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host diseaseEuropean Journal of Immunology, 2008
- Immunomodulatory properties of mesenchymal stromal cellsBlood, 2007
- Role for Interferon-γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem CellsStem Cells, 2005
- Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradationBlood, 2004
- Atopic dermatitisThe Lancet, 2003